241 related articles for article (PubMed ID: 37672530)
1. Hemophilia Gene Therapy: The End of the Beginning?
De Wolf D; Singh K; Chuah MK; VandenDriessche T
Hum Gene Ther; 2023 Sep; 34(17-18):782-792. PubMed ID: 37672530
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
4. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
5. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for hemophilia.
Nathwani AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):569-578. PubMed ID: 36485127
[TBL] [Abstract][Full Text] [Related]
7. What´s new in Gene Therapy of Hemophilia.
Rodriguez-Merchan EC
Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
[TBL] [Abstract][Full Text] [Related]
9. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
[TBL] [Abstract][Full Text] [Related]
11. Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.
Dougherty JA; Dougherty KM
Ann Pharmacother; 2023 Nov; ():10600280231202247. PubMed ID: 37978816
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec.
Anguela XM; High KA
Blood Adv; 2024 Apr; 8(7):1796-1803. PubMed ID: 38592711
[TBL] [Abstract][Full Text] [Related]
13. Viral vector-mediated gene therapy for hemophilia.
VandenDriessche T; Collen D; Chuah MK
Curr Gene Ther; 2001 Sep; 1(3):301-15. PubMed ID: 12109144
[TBL] [Abstract][Full Text] [Related]
14. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
15. Liver Gene Therapy.
Nathwani AC; McIntosh J; Sheridan R
Hum Gene Ther; 2022 Sep; 33(17-18):879-888. PubMed ID: 36082993
[TBL] [Abstract][Full Text] [Related]
16. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for hemophilia.
Chuah MK; Collen D; VandenDriessche T
J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
[TBL] [Abstract][Full Text] [Related]
18. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
19. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for the hemophilias.
VandenDriessche T; Collen D; Chuah MK
J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
